NRAS is altered in 9.09% of juvenile myelomonocytic leukemia patients [4].

NRAS Mutation (somatic) is an inclusion criterion in 2 clinical trials for juvenile myelomonocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain NRAS Mutation (somatic) and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 2 (1 open) [5].

NRAS Mutation (somatic) is an inclusion criterion in 2 clinical trials for neurofibromatosis type 1, of which 1 is open and 1 is closed. Of the trials that contain NRAS Mutation (somatic) and neurofibromatosis type 1 as inclusion criteria, 2 are phase 2 (1 open) [5].

NRAS is altered in 23.35% of chronic myelomonocytic leukemia patients [4].

NRAS Mutation (somatic) is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains NRAS Mutation (somatic) and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [5].

NRAS is altered in 7.91% of refractory anemia with excess blasts patients [4].

NRAS Mutation (somatic) is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 0 are open and 1 is closed. Of the trial that contains NRAS Mutation (somatic) and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (0 open) [5].

NRAS is altered in 3.65% of myelodysplastic syndromes patients [4].

NRAS Mutation (somatic) is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 0 are open and 1 is closed. Of the trial that contains NRAS Mutation (somatic) and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (0 open) [5].